Clinical relationship between Hashimoto's thyroiditis and papillary thyroid cancer

Acta Oncologica

Volumn 50, Issue 8, 2011, Pages 1228-1234

  Ahn, Dongbin ^a   Heo, Sung Jae ^a   Park, Ji Hyun ^a   Kim, Jae Hyug ^a   Sohn, Jin Ho ^a   Park, Ji Young ^a   Park, Sun Kyun ^b   Park, Junesik ^a  

^a Kyungpook National University Hospital   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HASHIMOTO DISEASE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; ONSET AGE; PAPILLARY THYROID CANCER; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SURGICAL PATIENT; THYROID CANCER; THYROID SURGERY; TUMOR VOLUME;

ADULT; CARCINOMA, PAPILLARY; FEMALE; HASHIMOTO DISEASE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REPUBLIC OF KOREA; THYROID NEOPLASMS;

EID: 80155195097     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.602109     Document Type: Article

References (25)

1. Tang KT, Lee CH. BRAF mutation in papillary thyroid carcinoma: Pathogenic role and clinical implications. J Chin Med Assoc. 2010;73:113-28.
2. Kwak JY, Kim EK, Kim JK, Han JH, Hong SW, Park TS, et al. Dual priming oligonucleotide-based multiplex PCR analysis for detection of BRAFV600E mutation in FNAB samples of thyroid nodules in BRAFV600E mutationprevalent area. Head Neck. 2010;32:490-8.
3. Cipolla C, Sandonato L, Graceffa G, Fricano S, Torcivia A, Vieni S, et al. Hashimoto thyroiditis coexistent with papillary thyroid carcinoma. Am Surg. 2005;71:874-8.
4. Lal G, Clark OH. Chronic thyroiditis. Textbook of endocrine: Surgery. Philadelphia: Saunders; 2005.
5. Singh B, Shaha AR, Trivedi H, Carew JF, Poluri A, Shah JP. Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: Impact on presentation, management, and outcome. Surgery. 1999;126:1070 - 6; discussion 1076-7.
6. Kumar V, Robbins SL. The endocrine system. Robbins basic pathology. Philadelphia: Saunders/Elsevier; 2007.
7. Coussens LM, Werb Z. Infl ammation and cancer. Nature. 2002;420:860-7.
8. Dailey M, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg. 1955;70:291-7.
9. Holm LE, Blomgren H, Lowhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med. 1985;312:601-4.
10. Crile GJ. Struma lymphomatosa and carcinoma of the thyroid. Surg Gynecol Obstet. 1978;147:350-2.
11. Shands WC. Carcinoma of the thyroid in association with struma lymphomatosa (Hashimoto's disease). Ann Surg. 1960;151:675-82.
12. Kim EY, Kim WG, Kim WB, Kim TY, Kim JM, Ryu JS, et al. Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2009;71: 581-6.
13. Sanders LE, Cady B. Differentiated thyroid cancer: Reexamination of risk groups and outcome of treatment. Arch Surg. 1998;133:419-25.
14. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050-7.
15. Shim YS, Lee YS, Lee GH, Lee BC, Jung YW, Lee JW, et al. Clinical assessment and management of papillary thyroid carcinoma with coexistent Hashimoto's thyroiditis. Korean J Otolaryngol - Head Neck Surg. 2007;50:537-1.
16. Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg. 2007;204:764-73.
17. Repplinger D, Bargren A, Zhang YW, Adler JT, Haymart M, Chen H. Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res. 2008;150:49-52.
18. Pisanu A, Piu S, Cois A,Uccheddu A. Coexisting Hashimoto's thyroiditis with differentiated thyroid cancer and benign thyroid diseases: Indications for thyroidectomy. Chir Ital. 2003;55:365-72.
19. Kashima K, Yokoyama S, Noguchi S, Murakami N, Yamashita H, Watanabe S, et al. Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid. 1998;8:197-202.
20. Loh KC, Greenspan FS, Dong F, Miller TR, Yeo PP. Infl uence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 1999;84:458-63.
21. McConahey WM. Hashimoto's thyroiditis. Med Clin North Am. 1972;56:885-96.
22. Wirtschafter A, Schmidt R, Rosen D, Kundu N, Santoro M, Fusco A, et al. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope. 1997;107:95-100.
23. Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, Papoff G, et al. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science. 1997;275:960-3.
24. Kimura H, Yamashita S, Namba H, Tominaga T, Tsuruta M, Yokoyama N, et al. Interleukin-1 inhibits human thyroid carcinoma cell growth. J Clin Endocrinol Metab. 1992;75: 596-602.
25. Kim SK, Song KH, Lim SD, Lim YC, Yoo YB, Kim JS, et al. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid. 2009;19:137-41.